FDA Considers Lifting Restrictions on Peptides Amid RFK Jr. Push
The U.S. Food and Drug Administration (FDA) is taking initial steps to potentially allow compounding pharmacies to produce seven previously restricted peptides. This move follows advocacy by Health and Human Services Secretary Robert F. Kennedy Jr., a vocal proponent of peptide therapy for conditions ranging from obesity to injury recovery. An expert advisory panel is scheduled to discuss the safety and efficacy of these substances in late July, with further reviews planned for early 2027. Kennedy argues that restoring regulated access will curb the dangerous black market fueled by the FDA's 2023 decision to categorize these peptides as high-risk. However, public health experts warn that many peptide claims remain untested and lack rigorous clinical trials. The debate highlights tensions between expanding patient access to customized medications and ensuring safety standards. Compounding pharmacies face pressure from patients seeking these treatments, while illicit sellers exploit regulatory gaps. The outcome of the upcoming advisory meetings could significantly reshape the availability of peptide-based therapies in the United States, impacting both legitimate medical practices and the gray market.
Wire timeline
FDA Considers Lifting Restrictions on Peptides Amid RFK Jr. Push
The U.S. Food and Drug Administration (FDA) is taking initial steps to potentially allow compounding pharmacies to produce seven previously restricted peptides. This move follows advocacy by Health and Human Services Secretary Robert F. Kennedy Jr., a vocal proponent of peptide therapy for conditions ranging from obesity to injury recovery. An expert advisory panel is scheduled to discuss the safety and efficacy of these substances in late July, with further reviews planned for early 2027. Kennedy argues that restoring regulated access will curb the dangerous black market fueled by the FDA's 2023 decision to categorize these peptides as high-risk. However, public health experts warn that many peptide claims remain untested and lack rigorous clinical trials. The debate highlights tensions between expanding patient access to customized medications and ensuring safety standards. Compounding pharmacies face pressure from patients seeking these treatments, while illicit sellers exploit regulatory gaps. The outcome of the upcoming advisory meetings could significantly reshape the availability of peptide-based therapies in the United States, impacting both legitimate medical practices and the gray market.
ashingtonpost